Recombinant Proteins

CELLXCHANGE recombinant protein and monoclonal antibody (mAb) development team are exlporing solitons for transforming the speed, efficiency, and precision of biologics production.

We currently working on following platforms, engineering, and manufacturing solutions:

Next-Generation Expression Systems

  • CRISPR/Cas9-engineered CHO cells: Tailored for higher yield and specific glycosylation patterns.
  • Synthetic biology platforms (e.g., E. coli, Pichia pastoris, insect cells) engineered for difficult-to-express proteins.
  • Cell-free protein synthesis: Enables rapid prototyping and screening without living cells.

Glycoengineering & PTM Control

  • Precise control of glycosylation, disulfide bond formation, and folding pathways for enhanced activity and stability.
  • Use of glycoSwitch® technology to humanize glycosylation in non-mammalian hosts.

High-Throughput Screening & AI Optimization

  • AI/ML algorithms for codon optimization, solubility prediction, and expression tuning.
  • Microfluidic and droplet-based screening platforms for rapid variant screening.

Stabilization Techniques

  • Protein engineering to enhance thermal stability, pH tolerance, and shelf-life.
  • Development of fusion proteins (e.g., Fc-fusion, albumin-fusion) to extend half-life.

Bispecific and Multispecific Antibodies

  • Target two or more antigens or antigen + effector cell (e.g., CD3 × tumor antigen).
  • Applications in oncology, autoimmunity, and infectious diseases (e.g., bispecific T-cell engagers or BiTEs).

Antibody-Drug Conjugates (ADCs)

  • More stable linkers, optimized payloads (e.g., cytotoxins, siRNA), and tumor-selective delivery.
  • Site-specific conjugation technologies improving homogeneity and efficacy.

Fc Engineering

  • Modified Fc regions to enhance ADCC, extend half-life, or reduce immunogenicity.
  • Fc-silent mAbs used to avoid unwanted immune activation in autoimmune or inflammatory settings.

mRNA-Encoded Antibodies

  • In vivo expression of therapeutic antibodies via mRNA (like mRNA vaccines).
  • Benefits: scalable production, rapid development, and non-invasive administration.